FGFR2-IN-1

CAS No. 2677709-76-9

FGFR2-IN-1( —— )

Catalog No. M35540 CAS No. 2677709-76-9

FGFR2-IN-1 is an FGFR inhibitor that inhibits FGFR1, FGFR2, and FGFR3 with IC50s of 460, 140, and 2200 nM, respectively.FGFR2-IN-1 can be used for the study of cancers associated with FGFR2.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 33 In Stock
5MG 56 In Stock
10MG 93 In Stock
25MG 158 In Stock
50MG 221 In Stock
100MG 334 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    FGFR2-IN-1
  • Note
    Research use only, not for human use.
  • Brief Description
    FGFR2-IN-1 is an FGFR inhibitor that inhibits FGFR1, FGFR2, and FGFR3 with IC50s of 460, 140, and 2200 nM, respectively.FGFR2-IN-1 can be used for the study of cancers associated with FGFR2.
  • Description
    FGFR2-IN-1 is a selective FGFR2 inhibitor with an IC50 of 140 nM.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Angiogenesis
  • Target
    FGFR
  • Recptor
    FGFR
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2677709-76-9
  • Formula Weight
    357.41
  • Molecular Formula
    C22H19N3O2
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    O=C(NC1=NNC=2C=C(C=CC12)C=3C=CC=C(OCC)C3)C=4C=CC=CC4
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Turner LD, et al. From Fragment to Lead: De Novo Design and Development toward a Selective FGFR2 Inhibitor. J. Med. Chem. 2021 Nov 15.
molnova catalog
related products
  • Amlexanox

    Amlexanox (AA673; CHX3673) is a specific inhibitor of IKKε and TBK1; inhibition of IKKε and TBK1 activity as determined by MBP phosphorylation showing an IC50 of approximately 1–2 μM.

  • FGFR2-IN-3

    FGFR2-IN-3 is an orally active selective FGFR2 inhibitor.

  • FGFR2-IN-2

    FGFR2-IN-2 is a specific FGFR2 inhibitor that inhibits FGFR1, FGFR2, and FGFR3, and can be used in the study of cancer and cardiovascular disease.